financetom
Business
financetom
/
Business
/
Members of K-pop group NewJeans say they are leaving agency after dispute
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Members of K-pop group NewJeans say they are leaving agency after dispute
Nov 28, 2024 7:20 AM

By Ju-min Park

SEOUL, Nov 28 (Reuters) - Members of NewJeans, one of

the most popular K-pop groups, said on Thursday that they were

leaving their agency ADOR, a subsidiary of powerhouse label HYBE

.

ADOR said however the agreement between it and the band

members "remains in full effect".

"Therefore, we respectfully request that the group continue

its collaboration with ADOR on upcoming activities, as has been

the practice to date," the firm said in a statement.

NewJeans has been caught up in infighting between executives

of the parent HYBE and ADOR's former chief executive who is the

band's creative director.

The latest controversy in the K-pop scene has gripped South

Korea this year, with accusations, audits and an emotional press

conference making headlines.

The five NewJeans members held a late-night press conference

to announce their departure from the agency and said they would

like to work with Min Hee-jin, ADOR's former chief who left the

agency this month.

"Once we leave ADOR, we'll aim to proceed freely with the

activities that we really desire," said Danielle, one of the

band members.

"We really wish to be able to release new music for Bunnies,

next year, as soon as possible, whenever," she said, referring

to their fans. "We really hope that we have the opportunity to

meet you guys from all around the world."

The members said they might not be able to use the band's

name once they terminated the contract with ADOR.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Levi Strauss Raises Fiscal 2024 Earnings Outlook Following First-Quarter Beat
Levi Strauss Raises Fiscal 2024 Earnings Outlook Following First-Quarter Beat
Apr 4, 2024
06:26 AM EDT, 04/04/2024 (MT Newswires) -- Levi Strauss (LEVI) shares advanced early Thursday after recording better-than-expected fiscal first-quarter results, buoyed by growth across all direct-to-consumer segments, prompting the apparel company to lift its full-year earnings outlook. Adjusted earnings are now set to come in between $1.17 and $1.27 a share for fiscal 2024, up from its previous guidance for...
Austria's RBI can't give timing on possible Strabag deal, CEO says
Austria's RBI can't give timing on possible Strabag deal, CEO says
Apr 4, 2024
VIENNA (Reuters) - Austria's Raiffeisen Bank International, the biggest Western bank in Russia, cannot give a timeframe for its contested deal to purchase a stake in Austria's Strabag that was long held by a now sanctioned Russian tycoon, the bank's chief executive said on Thursday. But Chief Executive Officer Johann Strobl told shareholders at an annual general meeting, the earlier...
Market Chatter: Google Mulls Charging Fees for Generative AI Features
Market Chatter: Google Mulls Charging Fees for Generative AI Features
Apr 4, 2024
06:35 AM EDT, 04/04/2024 (MT Newswires) -- Alphabet's (GOOG) Google ( GOOG ) is planning to add fees for use of new features powered by generative artificial intelligence, the Financial Times reported Thursday, citing people familiar with the matter. Google ( GOOG ) is studying options such as adding AI-powered search features to its existing premium subscription services, the report...
UK watchdog says Theramex-Viatris deal raises competition concerns
UK watchdog says Theramex-Viatris deal raises competition concerns
Apr 4, 2024
April 4 (Reuters) - Britain's competition watchdog said Theramex's purchase of European rights to two of Viatris' ( VTRS ) women's healthcare products ranges could lead to higher prices and lesser options for hormone replacement therapy treatments. Drugmaker Viatris agreed to sell its rights to Duphaston and Femoston product ranges to London-based Theramex in October. (Reporting by Prerna Bedi in...
Copyright 2023-2025 - www.financetom.com All Rights Reserved